Texas Oncology - Willowbrook
Welcome,         Profile    Billing    Logout  
 5 Trials 
20 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wu, Tao
NCT04385550: A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma

Not yet recruiting
3
528
RoW
Anlotinib hydrochloride capsule, AK105 injection, Paclitaxel injection, Docetaxel injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma
10/23
12/23
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer

Recruiting
3
360
RoW
PM8002, Nab-Paclitaxel, Placebo
Biotheus Inc.
Triple Negative Breast Cancer(TNBC)
07/27
07/28
TQ05105-III-01, NCT06682169: Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease

Recruiting
3
182
RoW
Rovadicitinib, Imatinib, Methotrexate, Mycophenolate mofetil, Rituximab
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Graft-versus-host Disease
10/29
12/30
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
NCT06300320: A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease

Recruiting
2
40
RoW
TQ05105 tablets
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chronic Graft Versus Host Disease
10/25
04/26
NCT05221658: A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC

Recruiting
2
60
RoW
HLX07+HLX10+ Cisplatin+5-FU, HLX07
Shanghai Henlius Biotech
ESCC or Esophageal Adenosquamous Carcinoma
06/24
08/25
TQB2102-II-02, NCT06452706: The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Recruiting
2
42
RoW
TQB2102 for injection
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Breast Cancer
06/26
06/28
NCT05033132: A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer

Withdrawn
2
177
RoW
Balstilimab, Balstilimab + Zalifrelimab
Agenus Inc., Betta Pharmaceuticals Co., Ltd.
Cervical Cancer
12/24
12/24
PM8002-A001, NCT05918445: PM8002 in the Treatment of Patients With Advanced Solid Tumors

Recruiting
1/2
380
RoW
PM8002
Biotheus Inc.
Malignant Neoplasm
11/25
11/25
TQB2223-I-01, NCT05894421: TQB2223 Injection in Combination With Penpulimab in Patients With Advanced Cancers

Recruiting
1
92
RoW
TQB2223 injection+ Penpulimab Injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Cancer
01/25
01/26
NCT05872360: To Investigate Effects of Amway Bundle Combination of Products on Osteoarthritis & Sarcopenia

Completed
N/A
240
RoW
Bundle Group 1 with Nutrilite Lifestyle, Bundle Group 2 without Nutrilite Lifestyle, Control Group 1, Control Group 2 with Nutrilite Lifestyle
Amway (China) R&D Center
Osteoarthritis, Sarcopenia
02/24
02/24
xiong, huihua
RC48-C012, NCT04400695: A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

Recruiting
3
366
RoW
RC48-ADC, RC48, Paclitaxel Injection, Taxol, Docetaxel Injection, Taxotere, Vinorelbine Tartrate Injection, Navelbine, Capecitabine Tablets, Xeloda
RemeGen Co., Ltd.
Breast Cancer
06/24
12/24
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
TQB2102-III-01, NCT06561607: A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer

Not yet recruiting
3
542
RoW
TQB2102 for Injection, Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Breast Cancer
01/27
12/28
RC48-C006, NCT03500380: A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

Active, not recruiting
2/3
301
RoW
RC48-ADC, RC48, Lapatinib, Capecitabine
RemeGen Co., Ltd.
Breast Neoplasms, Breast Diseases, Capecitabine, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma, HER2-positive Advanced Breast With Liver Metastases
07/24
12/24
Malik, Henna
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
BTX-BCI-016-PRT, NCT04875351: Breast Cancer Index (BCI) Registry

Active, not recruiting
N/A
3465
US
Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test, Breast Cancer Index (BCI) Test
Biotheranostics, Inc.
Breast Cancer
12/28
12/28
Thachil, John
FLEX, NCT03053193: MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

Recruiting
N/A
30000
Europe, Canada, US, RoW
MammaPrint, BluePrint, and Full-Genome Testing, MammaPrint, BluePrint
Agendia
Breast Cancer
04/37
12/37
Shojaie, Kerrie M
BTX-BCI-016-PRT, NCT04875351: Breast Cancer Index (BCI) Registry

Active, not recruiting
N/A
3465
US
Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test, Breast Cancer Index (BCI) Test
Biotheranostics, Inc.
Breast Cancer
12/28
12/28
Baig, Haris
No trials found
Todora, Jennifer
No trials found

Download Options